349 related articles for article (PubMed ID: 16385886)
1. [Efavirenz--comprehensive status of studies].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
[No Abstract] [Full Text] [Related]
2. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
van Leth F; Lange JM
Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
Fraaij PL; Neubert J; Bergshoeff AS; van Rossum AM; Hartwig NG; Schroten H; Korn K; Burger DM; de Groot R; Niehues T
Antivir Ther; 2004 Apr; 9(2):297-9. PubMed ID: 15134193
[TBL] [Abstract][Full Text] [Related]
4. Non-nucleoside reverse transcriptase inhibitors--an overview.
Bell C; Matthews GV; Nelson MR
Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
[No Abstract] [Full Text] [Related]
5. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
[No Abstract] [Full Text] [Related]
6. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
Reekie J; Reiss P; Ledergerber B; Sedlacek D; Parczewski M; Gatell J; Katlama C; Fätkenheuer G; Lundgren JD; Mocroft A;
HIV Med; 2011 May; 12(5):259-68. PubMed ID: 20812948
[TBL] [Abstract][Full Text] [Related]
7. NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F; Torralba M
J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
[No Abstract] [Full Text] [Related]
8. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
Torre D; Tambini R; Speranza F
HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
[TBL] [Abstract][Full Text] [Related]
9. HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
Meyer-Kleinmann J
Infection; 2004 Jun; 32(3):7. PubMed ID: 15230276
[No Abstract] [Full Text] [Related]
10. [Reliability: nevirapine. Highly effective + favorable influence on lipid profile].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():42-3. PubMed ID: 16385872
[No Abstract] [Full Text] [Related]
11. Switch study of nevirapine.
AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187109
[No Abstract] [Full Text] [Related]
12. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting adherence and convenience in antiretroviral therapy.
Lafeuillade A
Int J STD AIDS; 2001 Nov; 12 Suppl 4():18-24. PubMed ID: 11589824
[No Abstract] [Full Text] [Related]
14. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
[TBL] [Abstract][Full Text] [Related]
16. Comparison of NNRTIs in antiretroviral-naïve patients.
Arribas J
Int J STD AIDS; 2001 Nov; 12 Suppl 4():3-9. PubMed ID: 11589822
[No Abstract] [Full Text] [Related]
17. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
[TBL] [Abstract][Full Text] [Related]
18. Comparison of NNRTIs in antiretroviral-experienced patients.
Maggiolo F
Int J STD AIDS; 2001 Nov; 12 Suppl 4():10-7. PubMed ID: 11589823
[No Abstract] [Full Text] [Related]
19. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.
Manfredi R; Calza L; Chiodo F
AIDS; 2004 Nov; 18(17):2331-3. PubMed ID: 15577549
[TBL] [Abstract][Full Text] [Related]
20. The tolerability of efavirenz after nevirapine-related adverse events.
Clarke S; Harrington P; Barry M; Mulcahy F
Clin Infect Dis; 2000 Sep; 31(3):806-7. PubMed ID: 11017835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
